Literature DB >> 22884423

Myelination and oxidative stress alterations in the cerebellum of the G72/G30 transgenic schizophrenia mouse model.

Michaela D Filiou1, Larysa Teplytska, David M Otte, Andreas Zimmer, Christoph W Turck.   

Abstract

G72/G30 is a primate-specific locus that has been repeatedly implicated as a risk factor in genetic studies of schizophrenia. The function of the longest G72 splice variant (LG72 protein) encoded by this locus is not fully understood. To investigate the role of the LG72 protein in vivo, we have generated transgenic (G72Tg) mice carrying the G72/G30 locus that exhibit schizophrenia-like symptoms. We investigated protein expression alterations in the cerebella of G72Tg compared to wild type (WT) mice using a proteomics approach based on in vivo(15)N metabolic labeling and quantitative mass spectrometry (MS). Our data revealed expression level differences of proteins involved in myelin-related processes, oxidative stress and mitochondrial function. Furthermore, in silico pathway analyses suggested common regulators and targets for the observed protein alterations. Our work sheds light on the functional role of the LG72 protein and pinpoints molecular correlates of schizophrenia-like behavior.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22884423     DOI: 10.1016/j.jpsychires.2012.07.004

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  15 in total

Review 1.  G72 primate-specific gene: a still enigmatic element in psychiatric disorders.

Authors:  Silvia Sacchi; Giorgio Binelli; Loredano Pollegioni
Journal:  Cell Mol Life Sci       Date:  2016-02-25       Impact factor: 9.261

Review 2.  Recent advances in quantitative neuroproteomics.

Authors:  George E Craft; Anshu Chen; Angus C Nairn
Journal:  Methods       Date:  2013-04-25       Impact factor: 3.608

3.  'Neuroinflammation' differs categorically from inflammation: transcriptomes of Alzheimer's disease, Parkinson's disease, schizophrenia and inflammatory diseases compared.

Authors:  Michaela D Filiou; Ahmed Shamsul Arefin; Pablo Moscato; Manuel B Graeber
Journal:  Neurogenetics       Date:  2014-06-15       Impact factor: 2.660

Review 4.  What Have Mass Spectrometry-Based Proteomics and Metabolomics (Not) Taught Us about Psychiatric Disorders?

Authors:  Christoph W Turck; Michaela D Filiou
Journal:  Mol Neuropsychiatry       Date:  2015-05-12

Review 5.  Pre-clinical models of neurodevelopmental disorders: focus on the cerebellum.

Authors:  Alexey V Shevelkin; Chinezimuzo Ihenatu; Mikhail V Pletnikov
Journal:  Rev Neurosci       Date:  2014       Impact factor: 4.353

6.  Genetic variation in the G72 gene is associated with increased frontotemporal fiber tract integrity.

Authors:  Thomas Nickl-Jockschat; Tony Stöcker; Axel Krug; Valentin Markov; Ivan I Maximov; Ruiwang Huang; Frank Schneider; Ute Habel; Simon B Eickhoff; Klaus Zerres; Markus M Nöthen; Marcella Rietschel; N Jon Shah; Jens Treutlein; Tilo Kircher
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-07-17       Impact factor: 5.270

Review 7.  Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis.

Authors:  Giles E Hardingham; Kim Q Do
Journal:  Nat Rev Neurosci       Date:  2016-01-14       Impact factor: 34.870

8.  Targeting glia cells: novel perspectives for the treatment of neuropsychiatric diseases.

Authors:  B Di Benedetto; R Rupprecht
Journal:  Curr Neuropharmacol       Date:  2013-03       Impact factor: 7.363

9.  Selective Mitochondrial Targeting Exerts Anxiolytic Effects In Vivo.

Authors:  Markus Nussbaumer; John M Asara; Larysa Teplytska; Michael P Murphy; Angela Logan; Christoph W Turck; Michaela D Filiou
Journal:  Neuropsychopharmacology       Date:  2015-11-16       Impact factor: 7.853

10.  A rare mutation of CACNA1C in a patient with bipolar disorder, and decreased gene expression associated with a bipolar-associated common SNP of CACNA1C in brain.

Authors:  E S Gershon; K Grennan; J Busnello; J A Badner; F Ovsiew; S Memon; N Alliey-Rodriguez; J Cooper; B Romanos; C Liu
Journal:  Mol Psychiatry       Date:  2013-08-27       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.